Can you use Oncotype for determining adjuvant therapy in a young, premenopausal woman with multifocal HR+ breast cancer s/p mastectomy with 2 positive lymph nodes?

There are no data yet that I am aware of (retrospective or prospective) for the use of Oncotype 21 gene assay to make treatment decisions in premenopausal women with node positive, estrogen receptor positive early stage breast cancer. The prospective RxPONDER trial will hopefully provide data on the use of Oncotype this subgroup of women.

In contrast, there are prospective data from the MINDACT trial (NEJM 2016) for the use of the Mammaprint 70 gene assay in younger women with node positive breas...